62584-58-1Relevant academic research and scientific papers
Three Step Synthesis of Fully and Differently Arylated Pyridines
Arita, Mao,Yokoyama, Soichi,Asahara, Haruyasu,Nishiwaki, Nagatoshi
, p. 466 - 474 (2020)
Condensation of β-(2-pyridyl)enamine and α,β-unsaturated ketone in the presence of FeCl3 under air afforded highly substituted pyridines. In this transformation, FeCl3 acted as not only an acid catalyst but also an oxidant for the in
Monofunctionalized 1,3,5,7-tetraarylazaBODIPYs and their application in the synthesis of AzaBODIPY based conjugates
Koch, Angira,Ravikanth, Mangalampalli
, p. 10775 - 10784 (2019/09/30)
A series of monofunctionalized 1,3,5,7-tetraarylazaBODIPYs containing functional groups such as p-hydroxymethyl phenyl, p-hydroxyphenyl, p-cyanophenyl, p-nitrophenyl, and p-formylphenyl groups at the 1-position of the azaBODIPY core were synthesized by mi
2,3,5 TRISUBSTITUTED PYRROLE DERIVATIVES AS TOPOISOMERASE INHIBITORS AND THERAPEUTIC USES THEREOF
-
Page/Page column 25; 30, (2017/03/14)
The compounds of Formula (1) having topoisomerase inhibitory effect includes [Formula should be inserted here] wherein, R1 is selected from a group consisting of H, OR5, optionally substituted C1-C12 alkyl, haloalkyl, C2-C12alkenyl, C2-C12alkynyl, C1-C12alkyloxy, C1-C12haloalkyloxy, C2-C10 heteroalkyl, C3- C12 cycloalkyl, C3-C12cycloalkenyl, C2- C12heterocycloalkyl, C2-C2 heterocycloalkenyl, C6-C18aryl, and C1-C18heteroaryl; R2, R3 and R4 are independently selected from a group consisting of H, halogen, CN, - NO2, SH, CF3, OH, CO2H, CONH2, OCF3, optionally substituted C1-C12alkyl, optionally substituted C1-C12haloalkyl optionally substituted C2-C12alkenyl, optionally substituted C2- C12alkynyl, optionally substituted C1-C12alkyloxy, optionally substituted C1- C12haloalkyloxy, optionally substituted C2-C12heteroalkyl, optionally substituted C3- C12cycloalkyl, optionally substituted C3-C12 cycloalkenyl, optionally substituted C2-C12 heterocycloalkyl, optionally substituted C2-C12 heterocycloalkenyl, optionally substituted C6- C18aryl, and optionally substituted C1-C18heteroaryl; R5 is selected H, optionally substituted C1-C12alkyl, optionally substituted C2- C12alkenyl, optionally substituted optionally substituted C1-C12 haloalkyl, optionally substituted C3-C12cycloalkyl, optionally substituted C6- C18aryl, and optionally substituted C1- Ci18heteroaryl; or a pharmaceutically acceptable salt, N-oxide, or prodrug thereof.
